David McIntyre - 14 Apr 2025 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Role
Chief Financial Officer
Signature
/s/ David McIntyre
Issuer symbol
IKT
Transactions as of
14 Apr 2025
Net transactions value
$0
Form type
4
Filing time
16 Apr 2025, 16:06:03 UTC
Next filing
07 Jan 2026
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKT Stock Option (Right to Buy) Award $0 +1,775,539 $0.000000 1,775,539 14 Apr 2025 Common Stock 1,775,539 $2.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this option shall vest and become exercisable on April 14, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued employment on each such vesting date.